{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:56:09Z","timestamp":1778500569231,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>It is well accepted that only a subset of individuals with diabetes is expected to progress to advanced retinopathy and is at risk of losing functional vision. It is, therefore, of major relevance to identify this subset of patients and when they enter into rapid progression. The Early Treatment Diabetic Retinopathy Study (ETDRS) severity scale is the classic gold standard for grading diabetic retinopathy progression. The fundus abnormalities seen in Diabetic Retinopathy can conceptually be split into three main phenotypes. Those resulting from retinal neurodegeneration, those related to an alteration of the Blood-Retinal Barrier and, finally, those resulting from ischemia. In eyes showing the ischemic phenotype, disease progression is characterized by an initial stage of increasing hypoperfusion involving initially the superficial capillary plexus with progressive involvement of the deep capillary plexus followed by an hyperperfusion response consisting of dilated shunt vessels and intraretinal microvascular abnormalities. Visual acuity is generally maintained as the retinopathy progresses to loss of visual acuity as a result of either clinically significant macular oedema (CSMO) or proliferative diabetic retinopathy (PDR). It is the microvascular changes that occur in response to the progressive capillary closure and the hyperperfusion response characterized by abnormally dilated shunt vessels that create the conditions for CSMO and PDR. Our present understanding of the progress of diabetic retinal disease indicates that prevention of the major vision-threatening complications, may be addressed by either halting the progressive ischemia which characterises the initial hypoperfusion stage or by targeting the angiogenic and inflammatory response that follows.<\/jats:p>","DOI":"10.1038\/s41433-025-03901-3","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T16:59:49Z","timestamp":1752253189000},"page":"2627-2634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Understanding nonproliferative diabetic retinopathy progression using noninvasive imaging"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-9850","authenticated-orcid":false,"given":"Jos\u00e9","family":"Cunha-Vaz","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-3604","authenticated-orcid":false,"given":"Lu\u00eds","family":"Mendes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8769-1355","authenticated-orcid":false,"given":"D\u00e9bora","family":"Reste-Ferreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"3901_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels, Belgium: 2021. Available at https:\/\/diabetesatlas.org\/idfawp\/resource-files\/2021\/07\/IDF_Atlas_10th_Edition_2021.pdf."},{"key":"3901_CR2","doi-asserted-by":"crossref","unstructured":"Sato Y, Lee Z, Hayashi Y. Subclassification of preproliferative diabetic retinopathy and glycemic control: relationship between mean hemoglobin A1C value and development of proliferative diabetic retinopathy. Jpn J Ophthalmol. 2001;45:523\u20137.","DOI":"10.1016\/S0021-5155(01)00380-X"},{"key":"3901_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0161-6420(95)31052-4","volume":"102","author":"R Klein","year":"1995","unstructured":"Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy XV: the long-term incidence of macular edema. Ophthalmology. 1995;102:7\u201316.","journal-title":"Ophthalmology"},{"key":"3901_CR4","doi-asserted-by":"crossref","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98:786\u2013806.","DOI":"10.1016\/S0161-6420(13)38012-9"},{"key":"3901_CR5","doi-asserted-by":"crossref","unstructured":"Wong K. Defining diabetic retinopathy severity. In: Browning D, editor. Diabetic Retinopathy. New York, NY: Springer; 2010. pp. 105\u201320.","DOI":"10.1007\/978-0-387-85900-2_5"},{"key":"3901_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.preteyeres.2014.03.003","volume":"41","author":"J Cunha-Vaz","year":"2014","unstructured":"Cunha-Vaz J, Ribeiro L, Lobo C. Phenotypes and biomarkers of diabetic retinopathy. Prog Retin Eye Res. 2014;41:90\u2013111.","journal-title":"Prog Retin Eye Res"},{"key":"3901_CR7","first-page":"1","volume":"8","author":"N Ashton","year":"1958","unstructured":"Ashton N. Diabetic microangiopathy. Adv Ophthalmol. 1958;8:1\u201384.","journal-title":"Adv Ophthalmol"},{"key":"3901_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/bjo.62.6.351","volume":"62","author":"JG Cunha-Vaz","year":"1978","unstructured":"Cunha-Vaz JG. Pathophysiology of diabetic retinopathy. British J Ophthalmol. 1978;62:351\u20135.","journal-title":"British J Ophthalmol"},{"key":"3901_CR9","doi-asserted-by":"crossref","unstructured":"Cogan DG, Kuwabara T. Capillary shunts in the pathogenesis of diabetic retinopathy. Diabetes. 1963;12:293\u2013300.","DOI":"10.2337\/diab.12.4.293"},{"key":"3901_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2337\/diab.33.1.97","volume":"33","author":"RL Engerman","year":"1984","unstructured":"Engerman RL, Kern TS. Experimental galactosemia produces diabetic-like retinopathy. Diabetes. 1984;33:97\u2013100.","journal-title":"Diabetes"},{"key":"3901_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/archopht.1990.01070110117035","volume":"108","author":"KadorP Akagi","year":"1990","unstructured":"Akagi KadorP, Takahashi Y, Ikebe Y, Wyman H, Kinoshita M. J. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol. 1990;108:1301\u20139.","journal-title":"Arch Ophthalmol"},{"key":"3901_CR12","doi-asserted-by":"crossref","unstructured":"Kern T, Engerman R. A mouse model of diabetic retinopathy. Arch Ophthalmol. 1996;114:986\u201390.","DOI":"10.1001\/archopht.1996.01100140194013"},{"key":"3901_CR13","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2337\/diab.42.6.820","volume":"42","author":"RL Engerman","year":"1993","unstructured":"Engerman RL, Kern TS. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes. 1993;42:820\u20135.","journal-title":"Diabetes"},{"key":"3901_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/sj.eye.6700348","volume":"17","author":"KM Warpeha","year":"2003","unstructured":"Warpeha KM, Chakravarthy U. Molecular genetics of microvascular disease in diabetic retinopathy. Eye. 2003;17:305\u201311.","journal-title":"Eye"},{"key":"3901_CR15","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.2337\/db07-1495","volume":"57","author":"K Hietala","year":"2008","unstructured":"Hietala K, Forsblom C, Summanen P, Groop PH. Heritability of proliferative diabetic retinopathy. Diabetes. 2008;57:2176\u201380.","journal-title":"Diabetes"},{"key":"3901_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41581-020-0278-5","volume":"16","author":"JB Cole","year":"2020","unstructured":"Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16:377\u201390.","journal-title":"Nat Rev Nephrol"},{"key":"3901_CR17","doi-asserted-by":"publisher","first-page":"e1002654","DOI":"10.1371\/journal.pmed.1002654","volume":"15","author":"MS Udler","year":"2018","unstructured":"Udler MS, Kim J, von Grotthuss M, Bon\u00e0s-Guarch S, Cole JB, Chiou J, et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 2018;15:e1002654.","journal-title":"PLoS Med"},{"key":"3901_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist E, Storm P, K\u00e4r\u00e4j\u00e4m\u00e4ki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3901_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pathophys.2017.07.001","volume":"24","author":"RS Eshaq","year":"2017","unstructured":"Eshaq RS, Aldalati AMZ, Alexander JS, Harris NR. Diabetic retinopathy: breaking the barrier. Pathophysiology. 2017;24:229\u201341.","journal-title":"Pathophysiology"},{"key":"3901_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1167\/iovs.12-10873","volume":"54","author":"M Lasta","year":"2013","unstructured":"Lasta M, Pemp B, Schmidl D, Boltz A, Kaya S, Palkovits S, et al. Neurovascular dysfunction precedes neural dysfunction in the retina of patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2013;54:842\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3901_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/bjo.59.11.649","volume":"59","author":"J Cunha-Vaz","year":"1975","unstructured":"Cunha-Vaz J, Faria de Abreu J, Campos A. Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol. 1975;59:649\u201356.","journal-title":"Br J Ophthalmol"},{"key":"3901_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2337\/diacare.10.6.777","volume":"10","author":"ML Daley","year":"1987","unstructured":"Daley ML, Watzke RC, Riddle MC. Early loss of blue-sensitive color vision in patients with type I diabetes. Diabetes Care. 1987;10:777\u201381.","journal-title":"Diabetes Care"},{"key":"3901_CR23","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1159\/000534553","volume":"66","author":"T Santos","year":"2023","unstructured":"Santos T, Santos AR, Almeida AC, Rocha AC, Reste-Ferreira D, Marques IP, et al. Retinal capillary nonperfusion in preclinical diabetic retinopathy. Ophthalmic Res. 2023;66:1327\u201334.","journal-title":"Ophthalmic Res"},{"key":"3901_CR24","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/jcm9051433","volume":"9","author":"IP Marques","year":"2020","unstructured":"Marques IP, Madeira MH, Messias AL, Santos T, Martinho ACV, Figueira J, et al. Retinopathy phenotypes in type 2 diabetes with different risks for macular edema and proliferative retinopathy. J Clin Med. 2020;9:1433.","journal-title":"J Clin Med"},{"key":"3901_CR25","doi-asserted-by":"publisher","first-page":"E2655","DOI":"10.1073\/pnas.1522014113","volume":"113","author":"EH Sohn","year":"2016","unstructured":"Sohn EH, Van Dijk HW, Jiao C, Kok PHB, Jeong W, Demirkaya N, et al. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc Natl Acad Sci USA. 2016;113:E2655\u201364.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3901_CR26","doi-asserted-by":"publisher","first-page":"100636","DOI":"10.1016\/j.xops.2024.100636","volume":"5","author":"SR Vavrek","year":"2025","unstructured":"Vavrek SR, Nalbant EK, Konopek N, Decker NL, Fawzi AA, Mieler WF, et al. Retinal vascular permeability in diabetic subjects without retinopathy compared with mild diabetic retinopathy and healthy controls. Ophthalmol Sci. 2025;5:100636.","journal-title":"Ophthalmol Sci"},{"key":"3901_CR27","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMra1005073","volume":"366","author":"DA Antonetti","year":"2012","unstructured":"Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366:1227\u201339.","journal-title":"N Engl J Med"},{"key":"3901_CR28","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1167\/iovs.07-0427","volume":"48","author":"J Kusari","year":"2007","unstructured":"Kusari J, Zhou S, Padillo E, Clarke KG, Gil DW. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 2007;48:5152\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3901_CR29","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2119\/molmed.2012.00008","volume":"18","author":"Y Liu","year":"2012","unstructured":"Liu Y, Leo LF, McGregor C, Grivitishvili A, Barnstable CJ, Tombran-Tink J. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice. Mol Med. 2012;18:1387\u2013401.","journal-title":"Mol Med"},{"key":"3901_CR30","doi-asserted-by":"publisher","first-page":"e7328","DOI":"10.1371\/journal.pone.0007328","volume":"4","author":"Y Feng","year":"2009","unstructured":"Feng Y, Wang Y, Stock O, Pfister F, Tanimoto N, Seelinger MW, et al. Vasoregression linked to neuronal damage in the rat with defect of polycystin-2. PLoS One. 2009;4:e7328.","journal-title":"PLoS One"},{"key":"3901_CR31","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1167\/iovs.10-5960","volume":"52","author":"A Lecleire-Collet","year":"2011","unstructured":"Lecleire-Collet A, Audo I, Aout M, Girmens JF, Sofroni R, Erginay A, et al. Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy. Invest Ophthalmol Vis Sci. 2011;52:2861\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3901_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1463-1326.2007.00795.x","volume":"10","author":"S Ejaz","year":"2008","unstructured":"Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab. 2008;10:53\u201363.","journal-title":"Diabetes Obes Metab"},{"key":"3901_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1055\/s-2005-861361","volume":"37","author":"HP Hammes","year":"2005","unstructured":"Hammes HP. Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res. 2005;37:39\u201343.","journal-title":"Horm Metab Res"},{"key":"3901_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12177-011-9072-8","volume":"4","author":"JJ Blom","year":"2011","unstructured":"Blom JJ, Giove TJ, Favazza TL, Akula JD, Eldred WD. Inhibition of the adrenomedullin\/nitric oxide signaling pathway in early diabetic retinopathy. J Ocul Biol Dis Info. 2011;4:70\u201382.","journal-title":"J Ocul Biol Dis Info"},{"key":"3901_CR35","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1096\/fj.03-1476fje","volume":"18","author":"AM Joussen","year":"2004","unstructured":"Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450\u20132.","journal-title":"FASEB J"},{"key":"3901_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","volume":"30","author":"J Tang","year":"2011","unstructured":"Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343\u201358.","journal-title":"Prog Retin Eye Res"},{"key":"3901_CR37","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2337\/db18-1077","volume":"68","author":"IP Marques","year":"2019","unstructured":"Marques IP, Alves D, Santos T, Mendes L, Santos AR, Lobo C, et al. Multimodal imaging of the initial stages of diabetic retinopathy: different disease pathways in different patients. Diabetes. 2019;68:648\u201353.","journal-title":"Diabetes"},{"key":"3901_CR38","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/jcm10091821","volume":"10","author":"J Cunha-Vaz","year":"2021","unstructured":"Cunha-Vaz J. A central role for ischemia and OCTA metrics to follow DR progression. J Clin Med. 2021;10:1821.","journal-title":"J Clin Med"},{"key":"3901_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.800004","volume":"15","author":"MH Madeira","year":"2021","unstructured":"Madeira MH, Marques IP, Ferreira S, Tavares D, Santos T, Santos AR, et al. Retinal neurodegeneration in different risk phenotypes of diabetic retinal disease. Front Neurosci. 2021;15:800004.","journal-title":"Front Neurosci"},{"key":"3901_CR40","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.2337\/db16-1453","volume":"66","author":"AR Santos","year":"2017","unstructured":"Santos AR, Ribeiro L, Bandello F, Lattanzio R, Egan C, Frydkjaer-Olsen U, et al. Functional and structural findings of neurodegeneration in early stages of diabetic retinopathy: cross-sectional analyses of baseline data of the EUROCONDOR project. Diabetes. 2017;66:2503\u201310.","journal-title":"Diabetes"},{"key":"3901_CR41","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1167\/iovs.13-11895","volume":"54","author":"S Nunes","year":"2013","unstructured":"Nunes S, Ribeiro L, Lobo C, Cunha-Vaz J. Three different phenotypes of mild nonproliferative diabetic retinopathy with different risks for development of clinically significant macular edema. Invest Ophthalmol Vis Sci. 2013;54:4595\u2013604.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3901_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000522527","volume":"245","author":"IP Marques","year":"2022","unstructured":"Marques IP, Ferreira S, Santos T, Madeira MH, Santos AR, Mendes L, et al. Association between neurodegeneration and macular perfusion in the progression of diabetic retinopathy: a 3-year longitudinal study. Ophthalmologica. 2022;245:335\u201341.","journal-title":"Ophthalmologica"},{"key":"3901_CR43","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamaophthalmol.2017.0080","volume":"135","author":"MK Durbin","year":"2017","unstructured":"Durbin MK, An L, Shemonski ND, Soares M, Santos T, Lopes M, et al. Quantification of retinal microvascular density in optical coherence tomographic angiography images in diabetic retinopathy. JAMA Ophthalmol. 2017;135:370\u20136.","journal-title":"JAMA Ophthalmol"},{"key":"3901_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40123-021-00437-z","volume":"11","author":"L Ribeiro","year":"2022","unstructured":"Ribeiro L, Marques IP, Coimbra R, Santos T, Madeira MH, Santos AR, et al. Characterization of one-year progression of risk phenotypes of diabetic retinopathy. Ophthalmol Ther. 2022;11:333\u201345.","journal-title":"Ophthalmol Ther"},{"key":"3901_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40123-022-00623-7","volume":"12","author":"IP Marques","year":"2023","unstructured":"Marques IP, Ribeiro ML, Santos TP, Mendes LG, Reste-Ferreira D, Santos AR, et al. Different risk profiles for progression of nonproliferative diabetic retinopathy: a 2-year study. Ophthalmol Ther. 2023;12:485\u2013500.","journal-title":"Ophthalmol Ther"},{"key":"3901_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1167\/tvst.13.5.22","volume":"13","author":"IP Marques","year":"2024","unstructured":"Marques IP, Ribeiro ML, Santos T, Reste-Ferreira D, Mendes L, Martinho ACV, et al. Patterns of progression of nonproliferative diabetic retinopathy using non-invasive imaging. Transl Vis Sci Technol. 2024;13:22.","journal-title":"Transl Vis Sci Technol"},{"key":"3901_CR47","doi-asserted-by":"publisher","first-page":"101206","DOI":"10.1016\/j.preteyeres.2023.101206","volume":"97","author":"NK Waheed","year":"2023","unstructured":"Waheed NK, Rosen RB, Jia Y, Munk MR, Huang D, Fawzi A, et al. Optical coherence tomography angiography in diabetic retinopathy. Prog Retin Eye Res. 2023;97:101206.","journal-title":"Prog Retin Eye Res"},{"key":"3901_CR48","doi-asserted-by":"publisher","first-page":"e0259811","DOI":"10.1371\/journal.pone.0259811","volume":"16","author":"JX Ong","year":"2021","unstructured":"Ong JX, Zandi R, Fawzi AA. Early-stage macular telangiectasia type 2 vascular abnormalities are associated with interdigitation zone disruption. PLoS One. 2021;16:e0259811.","journal-title":"PLoS One"},{"key":"3901_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-015-0005-8","volume":"1","author":"TE de Carlo","year":"2015","unstructured":"de Carlo TE, Romano A, Waheed NK, Duker JS. A review of optical coherence tomography angiography (OCTA). Int J Retin Vitreous. 2015;1:5.","journal-title":"Int J Retin Vitreous"},{"key":"3901_CR50","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1007\/s40123-024-01054-2","volume":"13","author":"AR Santos","year":"2024","unstructured":"Santos AR, Lopes M, Santos T, Reste-Ferreira D, Marques IP, Yamaguchi TCN, et al. Intraretinal microvascular abnormalities in eyes with advanced stages of nonproliferative diabetic retinopathy: comparison between UWF-FFA, CFP, and OCTA\u2014the RICHARD study. Ophthalmol Ther. 2024;13:3161\u201373.","journal-title":"Ophthalmol Ther"},{"key":"3901_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100632","volume":"5","author":"IP Marques","year":"2024","unstructured":"Marques IP, Reste-Ferreira D, Santos T, Mendes L, Martinho ACV, Yamaguchi TCN, et al. Progression of capillary hypoperfusion in advanced stages of nonproliferative diabetic retinopathy: 6-month analysis of RICHARD study. Ophthalmology Sci. 2024;5:100632.","journal-title":"Ophthalmology Sci"},{"key":"3901_CR52","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0002-9394(70)92273-7","volume":"69","author":"EM Kohner","year":"1970","unstructured":"Kohner EM, Henkind P. Correlation of fluorescein angiogram and retinal digest in diabetic retinopathy. Am J Ophthalmol. 1970;69:403\u201314.","journal-title":"Am J Ophthalmol"},{"key":"3901_CR53","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/medicina59030435","volume":"59","author":"Y Takamura","year":"2023","unstructured":"Takamura Y, Yamada Y, Inatani M. Role of microaneurysms in the pathogenesis and therapy of diabetic macular edema: a descriptive review. Medicina. 2023;59:435.","journal-title":"Medicina"},{"key":"3901_CR54","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.oret.2020.06.010","volume":"4","author":"JF Russell","year":"2020","unstructured":"Russell JF, Shi Y, Scott NL, Gregori G, Rosenfeld PJ. Longitudinal angiographic evidence that intraretinal microvascular abnormalities can evolve into neovascularization. Ophthalmol Retin. 2020;4:1146\u201350.","journal-title":"Ophthalmol Retin"},{"key":"3901_CR55","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3390\/jpm14090977","volume":"14","author":"L Mendes","year":"2024","unstructured":"Mendes L, Ribeiro L, Marques I, Lobo C, Cunha-Vaz J. Characterization and automatic discrimination between predominant hypoperfusion and hyperperfusion stages of NPDR. J Pers Med. 2024;14:977.","journal-title":"J Pers Med"},{"key":"3901_CR56","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/eye.2009.108","volume":"23","author":"TM Curtis","year":"2009","unstructured":"Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis?. Eye. 2009;23:1496\u2013508.","journal-title":"Eye"},{"key":"3901_CR57","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1097\/IAE.0000000000003479","volume":"42","author":"PS Silva","year":"2022","unstructured":"Silva PS, Liu D, Glassman AR, Aiello LP, Grover S, Kingsley RM, et al. Assessment of fluorescein angiography nonperfusion in eyes with diabetic retinopathy using ultrawide field retinal imaging. Retina. 2022;42:1302\u201310.","journal-title":"Retina"},{"key":"3901_CR58","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/IAE.0000000000004021","volume":"44","author":"AR Santos","year":"2024","unstructured":"Santos AR, Almeida AC, Rocha AC, Reste-Ferreira D, Marques IP, Cunha-Vaz Martinho A, et al. Central and peripheral involvement of the retina in the initial stages of diabetic retinopathy. Retina. 2024;44:700\u20136.","journal-title":"Retina"},{"key":"3901_CR59","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1152\/ajpheart.00005.2016","volume":"311","author":"EP Moran","year":"2016","unstructured":"Moran EP, Wang Z, Chen J, Sapieha PH, Smith LE, et al. Neurovascular cross talk in diabetic retinopathy: pathophysiological roles and therapeutic implications. Am J Physiol Heart Circ Physiol. 2016;311:738\u201349.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3901_CR60","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fimmu.2016.00444","volume":"7","author":"G Minhas","year":"2016","unstructured":"Minhas G, Sharma J, Khan N. Cellular stress response and immune signaling in retinal ischemia-reperfusion injury. Front Immunol. 2016;7:444.","journal-title":"Front Immunol"},{"key":"3901_CR61","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/archopht.122.4.552","volume":"122","author":"JohnH Kempen","year":"2004","unstructured":"Kempen JohnH, O\u2019Colmain BenitaJ, Leske MCristina, Haffner StevenM, Klein Ronald, Moss ScotE, et al. The prevalence of diabetic retinopathy among adults in the United States. Archives Ophthalmol. 2004;122:552\u201363.","journal-title":"Archives Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03901-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03901-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03901-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T11:02:40Z","timestamp":1758193360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03901-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":61,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3901"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03901-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LM and DR-F declare there are no conflicts of interest. JC-V reports grants from Bayer, Boehringer Ingelheim and Carl Zeiss Meditec and is a consultant for Bayer, Boehringer Ingelheim, Carl Zeiss Meditec and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}